Skip to main content

Table 3 Clinical outcomes

From: The cumulative live birth rate of recombinant follicle-stimulating hormone alfa verse urinary human follicle-stimulating hormone for ovarian stimulation in assisted reproductive technology cycles

Varibales uFSH
(n = 764)
rFSH-alfa
(n = 314)
P
CLBR 329 (43.1%) 168 (53.5%) 0.002
Time to first live birth (days) 404.0 (357.0–496.0) 392.0 (356.0–452.8) 0.471
Fresh embryo transfer, n 201 (26.3%) 110 (35.0%) 0.005
 Pregnancy, n/N (%) 68/201 (33.8%) 36/110 (32.7%) 0.844
 Abortion 8/68 (11.8%) 4/36 (11.1%) 0.921
 Live birth 54/201 (26.9%) 28/110 (25.5%) 0.787
 Multiple birth 5/201 (2.5%) 9/110 (8.2%) 0.021
Frozen embryo transfer cycles 706 354  
 Pregnancy, n/N (%) 344/706 (48.7%) 169/354 (47.7%) 0.762
 Abortion 56/344 (16.3%) 23/169 (13.6%) 0.431
 Live birth 276/706 (39.1%) 142/354 (40.1%) 0.749
 Multiple birth 53/706 (7.5%) 28/354 (7.9%) 0.816
  1. CLBR Cumulative live birth rate; FSH follicle-stimulating hormone